Transcervical Ultrasound Identifies Primary Tumor Site of Unknown Primary Head and Neck Squamous Cell Carcinoma

Wojciech K. Mydlarz, MD¹, Jia Liu, MD¹, Ray Blanco, MD¹,², and Carole Fakhry, MD, MPH¹,²,³

No sponsorships or competing interests have been disclosed for this article.

Keywords
human papillomavirus, unknown primary, oropharyngeal cancer, ultrasound, head and neck squamous cell carcinoma

Received June 10, 2014; revised July 16, 2014; accepted August 7, 2014.

Head and neck squamous cell carcinomas (HNSCCs) of unknown primary site (UP) account for approximately 4% of HNSCCs.¹ These cases have historically been subclinical tumors arising from the nasopharynx, hypopharynx, or oropharynx. In the era of human papillomavirus (HPV)–positive HNSCCs, the presence of HPV in cervical malignancy of UP has been strongly associated with oropharyngeal primary tumors.² Tumors that are HPV–positive are typically small and arise from cryptic lingual and palatine lymphoid tissues, rendering primary tumor detection challenging.³ The traditional diagnostic paradigm for finding the primary tumor consists of a physical examination, fiber-optic laryngoscopy, and imaging. If these techniques are unsuccessful, operative examination under anesthesia is warranted, including direct laryngoscopy with “blind” biopsies directed at the nasopharynx, hypopharynx, oropharynx, larynx, and palatine and lingual tonsillectomy. Failure to identify the primary tumor site subsequently necessitates radiation of Waldeyer’s ring and concurrent chemotherapy. This report shows that transcervical ultrasound (US) can be used to localize oropharyngeal tumors. The study was reviewed and approved by the Greater Baltimore Medical Center Institutional Review Board.

Case Report
A 60-year-old white man, a former smoker and occasional drinker, presented with a 1-month history of enlarging left neck mass. By report, there was no evidence of a primary site clinically. Fine-needle aspiration (FNA) of the neck mass revealed nonkeratinizing squamous cell carcinoma.

Examination under anesthesia with direct laryngoscopy with biopsies of the base of tongue (BOT), nasopharynx, and bilateral palatine tonsillectomies failed to reveal the primary site.

The patient presented to our clinic for secondary evaluation with a 2-cm left level II cervical lymph node. There was no evidence of a primary tumor on physical or fiber-optic examinations. Review of the FNA confirmed the cytologic diagnosis of p16-positive squamous cell carcinoma. Positron emission tomography/computed tomography (PET/CT) revealed small foci of uptake without CT abnormality in the right nasopharynx (standardized uptake value [SUV] 5.6) and retropharynx (SUV 4.3) and 2 enlarged left level II lymph nodes measuring 1.7 × 2.3 cm and 1.2 × 0.7 cm with SUVs of 7.5 and 4.1, respectively (Figure 1).

A transcervical US was performed, demonstrating a hypoechoic heterogeneous lesion deep in the left BOT approaching the vallecula (Figure 2). The 1.2-cm (superior-inferior), 1.2-cm (anterior-posterior), and 1.3-cm (medial-lateral) mass was ill defined and purely endophytic. On parasagittal view, the lesion appeared to be approximately 9.2 mm from the mucosal surface of the BOT apex and 3.5 mm from the mucosal surface of the vallecula.

Direct laryngoscopy was again inconclusive. Directed deep biopsies based on the preoperative US revealed at least squamous cell carcinoma in situ. The patient was treated with cisplatin, concurrent with standard fractionation external beam radiation. Posttreatment PET/CT revealed no evidence of disease, and the patient is free of disease at 2 years.

¹Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins Medicine, Baltimore, Maryland, USA
²Milton J. Dance Jr Head and Neck Cancer Center, Greater Baltimore Medical Center, Baltimore, Maryland, USA
³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Corresponding Author:
Carole Fakhry, MD, MPH, Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins Medicine, 601 N Caroline Street, 6th Floor, Baltimore, MD 21287-0910, USA.
Email: cfakhry@jhmi.edu

Downloaded from oto.sagepub.com at SOCIEDADE BRASILEIRA DE CIRUR on January 17, 2015
Discussion

This case demonstrates the successful application of preoperative transcervical US to visualize a BOT malignancy and to help direct biopsies in a patient who would otherwise have been treated as having HNSCC of UP. Ultrasonography is low risk, inexpensive, and repeatable, and it can be performed easily in an office setting. Alternative approaches for this patient would be to perform lingual tonsillectomy for diagnostic purposes or to treat the entire pharyngeal axis with radiation for UP.\textsuperscript{1} Lingual tonsillectomy has inherent risks of anesthesia, bleeding, dysphagia, pain, and delay in definitive radiotherapy. In this case, it is also possible that a lingual tonsillectomy may not have detected this deep-seated tumor. The UP tumor treatment includes the entire pharyngeal axis and unnecessarily exposes the constrictor muscles and mucosa to radiation, thereby increasing the risk of acute and chronic side effects while also underdosing a potentially targetable and curable cancer.

In this case, US enabled identification of the primary lesion when PET/CT failed to reveal any abnormality in the oropharynx. Similarly, there was no asymmetry or mass on CT. Instead, the US revealed a small endophytic lesion deep in the tongue base without any clinically appreciable overlying mucosal changes or palpable abnormality. Indeed, this BOT lesion was identified despite previously performed blind biopsies. Ultrasound-guided transcervical FNA biopsy of the tongue base is feasible,\textsuperscript{4} and the use of US to search for the primary site of UP HNSCC has been previously reported.\textsuperscript{5} Oropharyngeal US may have utility in the evaluation of UP and oropharyngeal HNSCCs, but further investigation is necessary.

Author Contributions

Wojciech K. Mydlarz, acquisition, analysis and interpretation of data, revising, final approval; Jia Liu, acquisition, analysis and interpretation of data, final approval; Ray Blanco, data analysis, manuscript revision, final approval; Carole Fakhry, acquisition, analysis, manuscript conception, design, drafting, revising, final approval.
Disclosures

Competing interests: None.
Sponsorships: None.
Funding source: None.

References